Science Letter Archive

2024

No articles available for this year.

2023

No articles available for this year.

2022

No articles available for this year.

2021

No articles available for this year.

2020

No articles available for this year.

2019

No articles available for this year.

2018

No articles available for this year.

2017

November, 2017
A NEW SET OF TOOLS for investigating species differences in MDR1- and BCRP-mediated drug transporter activity

April, 2017
Assessing In Vitro Toxicology Using Hepatopac® Micropatterned Co- Culture (MPCC) Of Primary Hepatocytes

April, 2017
Investigate Enzyme-Transporter Interplay Using Hepatopac® Micropatterned Co-Culture (MPCC) Primary Hepatocytes

April, 2017
Metabolite Identification Using Hepatopac® Micropatterned Co-Culture (MPCC) Of Primary Hepatocytes

April, 2017
Metabolic Clearance Using Hepatopac® Co- Micropatterned Culture (MPCC) Of Primary Hepatocytes

2016

No articles available for this year.

2015

No articles available for this year.

2014

No articles available for this year.

2013

No articles available for this year.

2012

No articles available for this year.

2011

November, 2011
Cross-validation of in vitro and in vivo assay systems for assessing P-gp interactions at the BBB

April, 2011
Overexpression of P-gp (MDR1) does not confer resistance to its selective substrate Seliciclib

2010

October, 2010
Possible role of the BCRP multidrug transporter in rheumatoid arthritis therapy

2009

March, 2009
PREDEASY Mouse Bsep ATPase assay

2008

December, 2008
Agrochemicals interact specifically with human ABC transporters

July, 2008
Implications of BCRP in disease modifying anti-rheumatic drugs resistance

2007

June, 2007
Cholesterol on the rescue: HT screening of ABCG2 transporter - drug interactions

2006

No articles available for this year.

2005

November, 2005
In Vitro ABC Transporter Assays for Nutrient Absorption and Drug-Nutrient interaction studies

September, 2005
Effects of flavonoids on P-Glycoprotein activity

August, 2005
Our first Science letter: Efflux transporters: boon or blight for big pharma?